Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
Publication
, Conference
Choueiri, TK; Hessel, C; Halabi, S; Sanford, B; Hahn, O; Michaelson, MD; Walsh, M; Olencki, T; Picus, J; Small, EJ; Dakhil, S; Scheffold, C ...
Published in: ANNALS OF ONCOLOGY
September 1, 2017
Duke Scholars
Published In
ANNALS OF ONCOLOGY
EISSN
1569-8041
ISSN
0923-7534
Publication Date
September 1, 2017
Volume
28
Location
Madrid, SPAIN
Publisher
OXFORD UNIV PRESS
Conference Name
42nd European-Society-for-Medical-Oncology Congress (ESMO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Choueiri, T. K., Hessel, C., Halabi, S., Sanford, B., Hahn, O., Michaelson, M. D., … Morris, M. J. (2017). Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC). In ANNALS OF ONCOLOGY (Vol. 28). Madrid, SPAIN: OXFORD UNIV PRESS.
Choueiri, T. K., C. Hessel, S. Halabi, B. Sanford, O. Hahn, M. D. Michaelson, M. Walsh, et al. “Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC).” In ANNALS OF ONCOLOGY, Vol. 28. OXFORD UNIV PRESS, 2017.
Choueiri TK, Hessel C, Halabi S, Sanford B, Hahn O, Michaelson MD, et al. Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC). In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2017.
Choueiri, T. K., et al. “Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC).” ANNALS OF ONCOLOGY, vol. 28, OXFORD UNIV PRESS, 2017.
Choueiri TK, Hessel C, Halabi S, Sanford B, Hahn O, Michaelson MD, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Scheffold C, George DJ, Morris MJ. Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC). ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2017.
Published In
ANNALS OF ONCOLOGY
EISSN
1569-8041
ISSN
0923-7534
Publication Date
September 1, 2017
Volume
28
Location
Madrid, SPAIN
Publisher
OXFORD UNIV PRESS
Conference Name
42nd European-Society-for-Medical-Oncology Congress (ESMO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis